RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC.

被引：0
|
作者：
Crawford, Jeffrey [1 ]
Prado, Carla M. M. [2 ]
Hancock, Michael L. [3 ]
Johnston, Mary A. [3 ]
Dalton, James T. [3 ]
Steiner, Mitchell S. [3 ]
机构：
[1] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA
[2] Florida State Univ, Tallahassee, FL 32306 USA
[3] Gtx Inc, Memphis, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
muscle wasting; cachexia; NSCLC; enobosarm;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-026
引用
收藏
页码：S1199 / S1199
页数：1
相关论文
共 50 条
  • [21] Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
    Fautrel, Bruno
    Jia, Bochao
    Wu, Jianmin
    Ji, Ju
    Birt, Julie
    Haladyj, Ewa
    Takeuchi, Tsutomu
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2549 - 2551
  • [22] Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
    Combe, Bernard
    Nash, Peter
    Adams, David
    Kerr, Lisa
    Benichou, Olivier
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [23] Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials
    Mazieres, Julien
    Rittmeyer, Achim
    Gadgeel, Shirish
    Hida, Toyoaki
    Gandara, David R.
    Cortinovis, Diego L.
    Barlesi, Fabrice
    Yu, Wei
    Matheny, Christina
    Ballinger, Marcus
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : 140 - 150
  • [24] Sustained efficacy of lasmiditan: Results from phase 3 randomized clinical trials for acute treatment of migraine
    Doty, E. G.
    Krege, J.
    Jin, L.
    Raskin, J.
    Singh, R. Halker
    Kalidas, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 139 - 139
  • [25] Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials
    Colloca, Luana
    Dworkin, Robert H.
    Farrar, John T.
    Tive, Leslie
    Yang, Jiyue
    Viktrup, Lars
    Dasic, Gorana
    West, Christine R.
    Whalen, Ed
    Brown, Mark T.
    Gilbert, Steven A.
    Verburg, Kenneth M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (04) : 878 - 886
  • [26] POOLED SAFETY DATA FROM TWO PHASE 3 TRIALS OF A VAGINAL PH MODULATOR: RESULTS FROM AMPOWER AND AMP001
    Lee, T.
    Culwell, K.
    Dart, C.
    Howard, B.
    CONTRACEPTION, 2021, 104 (04) : 463 - 463
  • [27] The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials
    Dooley, Mary Anne
    Rovin, Brad H.
    Radhakrishnan, Jai
    Ginzler, Ellen M.
    Forrester, Tammy
    Anderson, Pamela
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [28] The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials
    Rovin, B. H.
    Dooley, M. A.
    Radhakrishnan, J.
    Ginzler, E. M.
    Forrester, T. D.
    Anderson, P. W.
    LUPUS, 2016, 25 (14) : 1597 - 1601
  • [29] The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
    Dalton, James T.
    Barnette, Kester G.
    Bohl, Casey E.
    Hancock, Michael L.
    Rodriguez, Domingo
    Dodson, Shontelle T.
    Morton, Ronald A.
    Steiner, Mitchell S.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2011, 2 (03) : 153 - 161
  • [30] Collagenase Clostridium Histolyticum-aaes for the Treatment of Cellulite in Women: Results From Two Phase 3 Randomized, Placebo-Controlled Trials
    Kaufman-Janette, Joely
    Joseph, John H.
    Kaminer, Michael S.
    Clark, James
    Fabi, Sabrina G.
    Gold, Michael H.
    Goldman, Mitchel P.
    Katz, Bruce E.
    Peddy, Kappa
    Schlessinger, Joel
    Young, V. Leroy
    Davis, Matthew
    Hurley, David
    Liu, Genzhou
    McLane, Michael P.
    Vijayan, Saji
    Bass, Lawrence S.
    DERMATOLOGIC SURGERY, 2021, 47 (05) : 649 - 656
12345